By David Bautz, PhD
NASDAQ:BCLI
READ THE FULL BCLI RESEARCH REPORT
Business Update
Topline Data from Phase 3 ALS Trial Before End of November 2020
BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) is currently conducting a Phase 3 clinical trial of NurOwn in patients with amyotrophic lateral sclerosis (ALS) (NCT03280056). A total of 200 patients were randomized 1:1 to receive NurOwn or placebo in the randomized, double blind, placebo controlled, multi-dose trial. Cells were extracted once from each patient prior to treatment, with all administrations of NurOwn derived from the same extraction of cells due to a cryopreservation process the company developed for long-term storage of mesenchymal stem cells (MSC). Just as with the companys prior studies, there was a 3-month run-in period prior to the first treatment with two additional NurOwn treatments occurring two and four months following the first treatment. The company is focusing the trial on faster-progressing ALS patients since those patients demonstrated superior outcomes in the Phase 2 trial of NurOwn. The primary outcome of the trial is the ALSFRS-R score responder analysis and we now anticipate topline results before the end of November 2020.
Update on Phase 2 Progressive Multiple Sclerosis Trial
BrainStorm is currently conducting a Phase 2 clinical trial of NurOwn in patients with progressive multiple sclerosis (MS) (NCT03799718). The trial is an open label, single arm study that is enrolling patients with progressive MS with Expanded Disability Status Scale (EDSS) scores of 3.0 6.5. The primary endpoint of the study is the safety and tolerability of three doses of NurOwn with secondary endpoints examining the timed 25-foot walking speed or 9-hole peg test (both validated MS clinical outcome assessments) along with paired cerebrospinal fluid (CSF) and blood biomarker analysis. The National Multiple Sclerosis Society awarded the company a $0.5 million grant to help fund the study.
The trial is now fully enrolled and we anticipate dosing to be completed for all patients by the end of 2020. While the company had previously considered performing an interim analysis, since topline data would be available soon after an interim analysis could be performed the company has decided against performing an interim analysis and will instead report topline data for all 20 patients when it becomes available.
NurOwn Derived Exosomes Show Promise in Preclinical ARDS Study
On July 23, 2020, BrainStorm announced the successful completion of the first milestone in developing an exosome-based platform for the treatment of severe acute respiratory distress syndrome (ARDS) caused by COVID-19. Exosomes are small vesicles (30-150 nm) that are secreted by all cell types. Exosomes from mesenchymal stem cells (MSCs), from which NurOwn is derived, can penetrate into deep tissues and deliver various bioactive molecules. In addition, they can be delivered both intravenously or intratracheally.
BrainStorm conducted a preclinical study of MSC-derived exosomes in a mouse model of lipopolysaccharide (LPS)-induced ARDS. Treatment with intratracheally administered exosomes resulted in a statistically significant improvement in various lung functions, including functional lung recovery and decreased lung damage, as judged by the lung disease severity score (P=0.03). In addition, they led to a reduction in a number of pro-inflammatory cytokines. Lastly, exosomes derived from MSC-NTF cells were superior to exosomes derived from nave MSC from the same donor.
We anticipate the results being submitted to a peer reviewed journal for publication and the company is currently deciding whether to initiate a clinical trial program in COVID-19 patients with ARDS.
Financial Update
On August 5, 2020, BrainStorm announced financial results for the second quarter of 2020. As anticipated, the company did not report any revenues during the second quarter of 2020. Net R&D expenses for the second quarter of 2020 were $5.7 million, compared to $3.6 million for the second quarter of 2019. The increase was primarily due to an increase in payroll and stock-based compensation and a decrease in support from the Israel Innovation Authority (IIA) and California Institute for Regenerative Medicine (CIRM) along with a decrease in costs related to the Phase 3 and Phase 2 clinical trials. Excluding participation from the IIA and CIRM, R&D expenses were $6.0 million in the second quarter of 2020, compared to $6.5 million in the second quarter of 2019. G&A expenses for the second quarter of 2020 were $1.7 million, compared to $1.3 million in the second quarter of 2019. The increase was primarily due to increased payroll and stock-based compensation.
Story continues
The company exited the second quarter of 2020 with approximately $16.2 million in cash, cash equivalents, and short-term investments. Subsequent to the end of the quarter, the company raised gross proceeds of approximately $13.7 million from the $50 million ATM facility entered into in March 2020 through the sale of 945,082 shares at an average price of $14.48 per share. In addition, the company raised gross proceeds of approximately $6.3 million from the exercise of warrants. We estimate that the company currently has approximately $35 million in cash, cash equivalents, and short-term investments.
As of July 31, 2020, the company had approximately 31.5 million shares outstanding and, when factoring in warrants and stock options, a fully diluted share count of approximately 37.0 million.
Conclusion
The countdown is on to the topline data release for the Phase 3 ALS trial, with those results expected before the end of November 2020. Even with the great run the stock has had since its recent lows in March 2020, we continue to view the shares as undervalued as we currently forecast peak sales for NurOwn of >$1 billion in ALS, >$500 million in MS, and >$2 billion in Alzheimers disease. We recently made a slight change to our model, in which we decreased the discount rate from 17% to 13%, and combined with the recent financing activity has resulted in an increase to our valuation to $33 per share.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCHtoreceive our articles and reports emailed directly to you each morning. Please visit ourwebsitefor additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $40,000 annually for these services. Full Disclaimer HERE.
Go here to read the rest:
BCLI: Phase 3 ALS Data Expected by the End of November 2020 - Yahoo Finance
- Stem Cell Therapy for Treatment of Ocular Disorders - Hindawi - December 27th, 2022
- Researchers find out why some stress is good for you - November 6th, 2022
- Shinya Yamanaka - Wikipedia - October 29th, 2022
- Implanting a Patient's Own Reprogrammed Stem Cells Shows Early Positive ... - October 29th, 2022
- World's first stem cell treatment for spina bifida delivered during fetal surgery - UC Davis Health - October 13th, 2022
- JDRF Announces the Appointment of Qizhi Tang, Ph.D., as Co-Director of The JDRF Center of Excellence in Northern California - PR Newswire - October 13th, 2022
- California court creates regulatory uncertainty over the FDA regulation of stem cell therapies - BioEdge - October 4th, 2022
- Scientists have created a mechanical womb that can grow life in the lab - Inverse - October 4th, 2022
- ISCT: California stem cell ruling is flawed and has inserted regulatory uncertainty into the CGT market - BioPharma-Reporter.com - September 16th, 2022
- Scientists Use Stem Cells to Create Synthetic Mouse Embryos - September 16th, 2022
- UK Equine Research Hall of Fame Inductees Announced - Equi Management - September 16th, 2022
- Cultured meat startup Prolific Machines unveils its Henry Ford approach to cell growth - TechCrunch - September 16th, 2022
- New Stem Cell Therapy Protects Brain Against the Neurological Disorder - Nature World News - September 8th, 2022
- Scientists Are Working on New and Improved Hair Loss Treatments - Gizmodo - September 8th, 2022
- What happens to the brain on prescription steroids? - Medical News Today - September 8th, 2022
- How this scientist uses Legos to explain the power of stem cells - August 30th, 2022
- CIRM Bridges intern researches stem cells to grow kidneys - August 30th, 2022
- Alzheimer's: Could controlling the brain's own clean-up crew help? - Medical News Today - August 22nd, 2022
- Trial to Compare Safety and Efficacy of Novel Cell Therapy to Standard of Care in Patients With Rare Blood Cancers - Curetoday.com - August 5th, 2022
- Medpoint Global was awarded the Best Revolutionary Hair Transplant Center of the Year and continues to follow developments in its field and offer more... - August 5th, 2022
- Cell Culture Media Market Worth $14.64 Billion by 2029 - Exclusive Report by Meticulous Research - GlobeNewswire - August 5th, 2022
- Haifan Lin takes on new role as President of the ISSCR - EurekAlert - July 3rd, 2022
- UCI-led team discovers signaling molecule that potently stimulates hair growth - UCI News - July 3rd, 2022
- Calidi Biotherapeutics Announces Appointment of W.K. Alfred Yung, M.D., to its Medical Advisory Board - Business Wire - July 3rd, 2022
- Organoids reveal similarities between myotonic dystrophy type 1 and Rett syndrome - EurekAlert - July 3rd, 2022
- Our View: Roe reversal hard hit to science - The Durango Herald - July 3rd, 2022
- Connection Map Reveals Changes in the Injured Brain - Technology Networks - June 22nd, 2022
- Scientists Used CRISPR to Trace Every Human Gene to Its Function - Singularity Hub - June 22nd, 2022
- Maike Sander named to lead the Max Delbrck Center - EurekAlert - June 22nd, 2022
- CRISPR-Cas12a Editing Rates Improve with Better Directions to the Nucleus - Genetic Engineering & Biotechnology News - June 22nd, 2022
- UB-led study presents critical step forward in understanding Parkinson's disease and how to treat it - University at Buffalo - June 13th, 2022
- Stem Cells: A Case for the Use of Human Embryos in Scientific Research - June 4th, 2022
- Top Beverly Hills Plastic Surgeon, Dr. John Anastasatos, Explores Cell-Assisted Lipotransfer (CAL) with Breast Augmentation in New Publication -... - June 4th, 2022
- Regenerative Medicine Market To Grow At A CAGR Of 11.27% By 2027, Due To Advancements In Cell Biology, Genomics Research, And Gene-Editing Technology... - June 4th, 2022
- Google Reverses Ban on Ads for All Stem Cell Therapies, Will Allow FDA-Approved Ones - Gizmodo Australia - May 15th, 2022
- Head-To-Head Survey: Jasper Therapeutics (NASDAQ:JSPR) & CytRx (OTCMKTS:CYTR) - Defense World - May 15th, 2022
- Primary Cell Culture Market Mechanical Separation Segment Is Expected To Witness A Lucrative CAGR Of 11.7% Till 2028, Owing To Advancements In... - May 15th, 2022
- Ray Therapeutics Receives $4M in Funding From the California Institute for Regenerative Medicine (CIRM) - BioSpace - May 2nd, 2022
- Predicting the Future of Food - Bon Appetit - May 2nd, 2022
- FDA Grants Direct Biologics Regenerative Medicine Advanced Therapy (RMAT) Designation for the use of ExoFlo in COVID-19 Related ARDS USA - English -... - April 19th, 2022
- Chronic Diseases Is Expected To Have Positive Impact On Stem Cell Characterization Kits Market Demand Bloomingprairieonline - Bloomingprairieonline - April 19th, 2022
- Cleveland Cord Blood Center and Deverra Therapeutics Announce Agreement - Yahoo Finance - April 6th, 2022
- A model that mimics malformation associated with severe epilepsy paves way to novel therapies - EurekAlert - March 25th, 2022
- Stem cell agency: Following the money - and its performance - Capitol Weekly - December 24th, 2021
- Epithelial Cell Culture Media Market to hit US$ 303040.33 thousand by 2028, at 11.4% CAGR: The Insight Partners - Digital Journal - December 24th, 2021
- What is Biohacking? Understanding the Silicon Valley Wellness Trend Youll Hear About in 2022 - SheKnows - December 24th, 2021
- Second Woman Spontaneously Clears HIV: 'We Think More Are Out - Medscape - November 22nd, 2021
- Business Partnership for Development and Commercialization of Medical Device Implant Utilizing MSC2 for the Regeneration of Esophageal Tissue in... - November 22nd, 2021
- Misinformation on stem cell treatments for COVID-19 linked to overhyped science, researchers argue - EurekAlert - October 16th, 2021
- Phase 2 Clinical Trial Data of NurOwn in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in... - October 16th, 2021
- StemExpress Partners with the Alliance for Regenerative Medicine to Provide COVID-19 Testing for the Cell and Gene Meeting on the Mesa - WSAW - October 5th, 2021
- BrainStorm to Present at the 2021 Cell & Gene Meeting on the Mesa - WWNY - October 5th, 2021
- UC Davis and the School of Medicine set new records in research funding - UC Davis Health - August 31st, 2021
- FDA gives speedy review to Bayer's Parkinson's stem cell therapy - - pharmaphorum - July 21st, 2021
- Stem cell model reveals how COVID-19 can infect the brain - Study Finds - July 21st, 2021
- Introducing the 3D bioprinted neural tissues with the potential to 'cure' human paralysis - 3D Printing Industry - July 21st, 2021
- Insception Lifebank and Cells for Life Join the Generate Life Sciences Family to Create a Global Platform - Canada NewsWire - June 6th, 2021
- Innovative Regenerative Medicine Therapies Safety Comes First - FDA.gov - June 6th, 2021
- ViaCyte to Present Late-Breaking Data at the American Diabetes Association's 81st Scientific Sessions - PRNewswire - June 6th, 2021
- Viral vector unlikely to be cause of leukemia in gene therapy patient - Science Magazine - March 11th, 2021
- Astrocytes Derived from Patients with Bipolar Disorder Malfunction - UC San Diego Health - March 11th, 2021
- Peer Recognition | The UCSB Current - The UCSB Current - March 11th, 2021
- Stem cells on the ballot - Science Magazine - January 20th, 2021
- Controlling the immune system with 'invisible stem' cells - BioNews - January 20th, 2021
- How a UCSF team is giving Cronutt the sea lion a second chance with neuroscience - University of California - October 20th, 2020
- What Proposition 14 Tells Us About California - The New York Times - October 20th, 2020
- California Proposition 14: Funding medical research that uses stem cells - KTLA - October 20th, 2020
- Technology to natures rescue - The Hindu - October 20th, 2020
- What You Need to Know About Prop 14, The Stem Cell Research Bond (Transcript) - KQED - October 5th, 2020
- UC Davis Engineers Lead $36M Effort to Improve Recovery From Spinal Cord Injuries - UC Davis - October 5th, 2020
- Dust off the crystal ball: It's time for STAT's 2020 Nobel Prize predictions - STAT - October 5th, 2020
- Stem Cells Offer Hope of Treatment for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS) - HospiMedica - September 15th, 2020
- David Shavelle, MD, Named Medical Director of Adult Cardiology for the MemorialCare Heart & Vascular Institute at Long Beach Medical Center -... - September 15th, 2020
- Seeing the eye like never before | Newsroom - UW Medicine Newsroom - September 15th, 2020
- Why The FDA's Recent Approval Of New Vaccine Is A Gigantic Win In The War On Cancer - Innovation & Tech Today - September 7th, 2020
- Gore partners with San Diego company on cell delivery system with potential to treat Type 1 diabetes - delawarebusinessnow.com - August 12th, 2020
- Celularity announces the activation of first California Clinical Trial Site following CIRM Grant Award to Advance Treatments for COVID-19 - PRNewswire - August 12th, 2020
- Meet The 12 Next-Gen Food Techs Transforming The Future Of Protein - Green Queen Media - August 12th, 2020
- BeyondSpring Initiates Expanded Access Program with Plinabulin for Patients Suffering from CIN in the US - BioSpace - August 12th, 2020
- Impact of COVID 19 pandemic on Stem Cell Characterization and Analysis Tools Market Structure and Its Segmentation - 3rd Watch News - July 1st, 2020